Targeting Signaling Transduction Pathways in Bladder Cancer

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Systemic therapy for urothelial carcinoma (UC) primarily uses cytotoxic chemotherapy.
• Recent next-generation sequencing (NGS) studies reveal genetic derangements in signaling pathways in UC.
• These genetic alterations, including point mutations and copy number alterations (CNA), are present across all disease stages.

Purpose of the Study:

• To review the rationale for targeted therapies in urothelial carcinoma treatment.
• To summarize the progress in studying signal transduction pathway inhibition for UC.
• To explore targeted therapies as a next step in managing localized and metastatic UC.

Main Methods:

• Review of recent clinical trials exploring targeted therapies.
• Analysis of next-generation sequencing (NGS) data identifying genetic alterations in UC.
• Examination of the role of signal transduction pathways in UC development and progression.

Main Results:

• Targeted therapies inhibiting specific signal transduction pathways are under investigation.
• Genetic derangements in signaling pathways are common in urothelial carcinoma.
• Targeted therapies offer potential for both localized and metastatic urothelial carcinoma.

Conclusions:

• Targeted therapies represent a promising evolution in urothelial carcinoma management.
• Inhibition of aberrant signal transduction pathways provides a targeted treatment strategy.
• Further research into targeted therapies is crucial for advancing UC treatment options.